The cd38 monoclonal antibodies market outlook remains robust, driven by their pivotal role in treating hematological malignancies such as multiple myeloma and B-cell lymphomas. High unmet clinical needs, coupled with the commercial success of established therapies like daratumumab, underscore the market’s attractiveness. Competitive intensity is moderate, with key players—including Johnson & Johnson, AbbVie, and Roche—dominating the landscape, but biosimilar entrants may intensify rivalry. Long-term growth is anticipated, fueled by expanding indications, combination therapies, and next-generation formats like bispecific antibodies. Innovation is accelerating, with a focus on enhancing efficacy through novel modalities and addressing resistance mechanisms. The demand-supply balance remains stable, though manufacturing complexities and immunogenicity risks pose challenges. Key risks include regulatory uncertainties, pricing pressures in mature markets, and the potential for immune-related adverse events. Strategic partnerships and R&D investments will be critical for sustaining market relevance in this high-growth segment.
